Invention Grant
- Patent Title: Human alpha-N-acetylgalactosaminidase polypeptide
-
Application No.: US16063408Application Date: 2016-12-22
-
Publication No.: US11040114B2Publication Date: 2021-06-22
- Inventor: Wouter Vervecken , Steven Geysens
- Applicant: Oxyrane UK Limited
- Applicant Address: GB Manchester
- Assignee: Oxyrane UK Limited
- Current Assignee: Oxyrane UK Limited
- Current Assignee Address: GB Manchester
- Agency: Fish & Richardson P.C.
- Priority: EP15202729 20151224
- International Application: PCT/EP2016/082304 WO 20161222
- International Announcement: WO2017/109034 WO 20170629
- Main IPC: C12N1/20
- IPC: C12N1/20 ; A61K48/00 ; C12N9/24 ; C12N15/81 ; A61P43/00 ; C12N15/80 ; A61K38/00
Abstract:
The present invention provides new forms of human α-N-acetylgalactosaminidase (NAGAL) polypeptide or a functionally active variant or fragment thereof, nucleic acids encoding the same, and related products and uses, including use in methods of treating Fabry disease, Schindler disease or Kanzaki disease.
Public/Granted literature
- US20180360991A1 HUMAN ALPHA-N-ACETYLGALACTOSAMINIDASE POLYPEPTIDE Public/Granted day:2018-12-20
Information query
IPC分类:
